-
1.发明公开
公开(公告)号：EP4276110A1
公开(公告)日：2023-11-15
申请号：EP22736572.3
申请日：2022-01-07
发明人： LIU, Jiawang , YANG, Yaping , ZHAO, Siqi , LIU, Yang , SONG, Nanmeng , FAN, Fei , SU, Kaixuan , ZHANG, Lanxin , WANG, Jing , XU, Jiangcheng , LEE, Kyoung Woo
IPC分类号： C07K16/28 , C12N15/13 , C12N15/63 , A61K39/395 , A61P35/00
摘要： Provided are an anti-PD-L1/anti-4-lBB natural antibody structure-like heterodimeric form bispecific antibody and a preparation thereof. Specifically, provided are an anti-PD-L1/anti-4-1BB bispecific antibody that has natural IgG features, that has no mismatch between heavy and light chains and that is in the form of a highly stable heterodimer, as well as a preparation method therefor. The bispecific antibody can simultaneously bind two target molecules and is more effective in treating complex diseases and has fewer side effects.
-
2.发明公开
公开(公告)号：EP4011390A1
公开(公告)日：2022-06-15
申请号：EP20849224.9
申请日：2020-08-06
发明人： LIU, Yanghan , MA, Yidong , WANG, Yinjue , ZHOU, Kaisong
IPC分类号： A61K39/395 , A61K9/08
摘要： The present invention relates to formulations comprising an anti-PD-1/HER2 bispecific antibody, and in particular to a pharmaceutical formulation comprising the anti-PD-1/HER2 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.
-
3.发明公开N-BENZOATE GROUP SUBSTITUTED BENZOPYRROLINE-2-ONE DERIVATIVE AND USE THEREOF 审中-公开N-苯甲酸酯基团取代的苯并吡咯啉-2-酮衍生物及其用途
公开(公告)号：EP3252038A1
公开(公告)日：2017-12-06
申请号：EP16742703.8
申请日：2016-01-22
发明人： XUE, Hai , ZHAO, Tao , CHA, Mi Young , KIM, Maengsup
IPC分类号： C07D209/08 , C07D209/10 , A61K31/404 , A61P29/00
CPC分类号： A61K31/404 , A61K31/03 , A61K31/192 , A61K31/196 , C07D209/08 , C07D209/10 , Y02A50/409
摘要： Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a RORγ mediated disease. The compound has the structural formula (I).
摘要翻译： 本发明公开了可用于预防或治疗RORγ介导的疾病的化合物，立体异构体及其互变异构体，其药学上可接受的盐及其溶剂化物或前药。 该化合物具有结构式（I）。
-
4.发明公开A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 有权药物组合物，癌的干扰素α缀合物的治疗
公开(公告)号：EP2753348A4
公开(公告)日：2015-05-27
申请号：EP12830783
申请日：2012-09-05
发明人： JUNG SUNG YOUB , WOO YOUNG EUN , LIM SE YOUNG , CHOI IN YOUNG , LEE JAE HO , KWON SE CHANG , MOON SUNG HWAN , LIU JIAWANG
IPC分类号： A61K38/21 , A61K39/395 , A61K47/30 , A61K47/48 , A61P35/00
CPC分类号： A61K47/642 , A61K9/0019 , A61K31/7068 , A61K38/212 , A61K47/48423 , A61K47/60 , A61K47/68
摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
摘要翻译： 一种用于预防或治疗癌症的方法包括抗癌药物组合物的施用包含干扰素α或其聚合物缀合物。 所述药物组合物可以共同给药的抗癌剂。 的干扰素α缀合物显示了在体内半衰期和比常规干扰素α更优异的抗癌活性的时间越长，并且特别地，其共同给予含有抗癌剂：如吉西他滨对癌症细胞的协同抑制效果 的生长和增殖，从而显示出显着优异的抗肿瘤活性。 此外，抗癌药物组合物具有优异的体内半衰期和抗癌活性大大降低给药频率。 抗癌剂和具有优异的抗癌活性的干扰素α缀合物的共施用降低抗癌剂的给药剂量，从而减少抗癌剂的副作用和提高患者的治疗顺应性。
-
公开(公告)号：EP4276111A1
公开(公告)日：2023-11-15
申请号：EP22736575.6
申请日：2022-01-07
发明人： LIU, Yang , ZHANG, Ruijing , FAN, Fei , LI, Xiaochun , YU, Lu , LIU, Jiawang , LEE, Kyoung Woo
IPC分类号： C07K16/28 , A61P35/00 , A61K39/395 , C12N15/13
摘要： Provided are an antibody specifically binding to 4-1BB and an antigen-binding fragment thereof. The antibody specifically binding to 4-1BB and the antigen-binding fragment of the antibody have high specificity, and after being binded to an antigen, the antibody and the antigen-binding fragment thereof can enhance an immune killing function of T cells, can induce activation of immune cells and promote secretion of cytokines, and can significantly inhibit the growth of tumors in the body.
-
6.发明公开
公开(公告)号：EP3735429A1
公开(公告)日：2020-11-11
申请号：EP19751154.6
申请日：2019-02-08
发明人： LIU, Jiawang , SONG, Nanmeng , YANG, Yaping , KIM, Maeng Sup , YAN, Yao , YIN, Qingqing
-
7.发明公开COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES 审中-公开VERBINDUNG ZUR HEMMUNG VONAKTIVITÄTENVON BTK- UND / ODER JAK3-KINASEN
公开(公告)号：EP3048105A4
公开(公告)日：2017-05-17
申请号：EP14846251
申请日：2014-09-18
发明人： LIU JINMING , CHA MI YOUNG , LI GONG , LI ZHANMEI , QIU HONGJUAN , KIM MAENGSUP
IPC分类号： C07D487/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61P1/00 , A61P7/02 , A61P11/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/02 , C07D491/048 , C07D495/04 , C07D519/00
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
-
8.发明公开COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES 审中-公开VERBINDUNG ZUR HEMMUNG VONAKTIVITÄTENVON BTK- UND / ODER JAK3-KINASEN
公开(公告)号：EP3048105A1
公开(公告)日：2016-07-27
申请号：EP14846251.8
申请日：2014-09-18
发明人： LIU, Jinming , CHA, Mi Young , LI, Gong , LI, Zhanmei , QIU, Hongjuan , KIM, Maengsup
IPC分类号： C07D487/04 , C07D491/048 , C07D495/04 , C07D519/00 , A61K31/53 , A61K31/519 , A61K31/5377 , A61P37/02 , A61P29/00 , A61P7/02 , A61P35/00 , A61P19/02 , A61P11/00 , A61P17/06 , A61P1/00
CPC分类号： C07D495/04 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K45/06 , C07D487/04 , C07D491/048 , C07D519/00 , A61K2300/00
摘要： The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula ( I ).
摘要翻译： 本发明涉及抑制Bruton酪氨酸激酶（BTK）和/或Janus激酶3（JAK3）的活性的化合物，该化合物的药物组合物，其药物应用，使用该化合物抑制活性的方法 BTK和/或JAK3，以及在哺乳动物（特别是人）中用于治疗和/或预防BTK和/或JAK3介导的疾病或病症的方法。 该化合物由结构式（I）表示。
-
9.发明公开A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 有权药物组合物，癌的干扰素α缀合物的治疗
公开(公告)号：EP2753348A1
公开(公告)日：2014-07-16
申请号：EP12830783.2
申请日：2012-09-05
发明人： JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
IPC分类号： A61K38/21 , A61K39/395 , A61K47/48 , A61K47/30 , A61P35/00
摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
-
公开(公告)号：EP4276466A1
公开(公告)日：2023-11-15
申请号：EP22736576.4
申请日：2022-01-07
发明人： LIU, Jiawang , FAN, Fei , LIU, Yang , WANG, Licui , LEE, Kyoung Woo
IPC分类号： G01N33/574 , C12N15/13 , C07K16/28 , A61P35/00 , A61K39/00
摘要： Provided are an antibody specifically binding to PD-L1 and an antigen-binding fragment thereof. The antibody and the antigen-binding fragment thereof have high specificity and stability, can specifically block a PD-L1-SIPRα pathway, do not cause hemagglutination within a certain concentration range, and thus can significantly suppress tumor growth in vivo.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.012 秒)
